Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simultaneous passive and active immunization against hepatitis A.

A Leentvaar-Kuijpers1, R A Coutinho, V Brulein

  • 1Municipal Health Service, Amsterdam, The Netherlands.

Vaccine
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Do not forget HIV in the Netherlands].

Nederlands tijdschrift voor geneeskunde·2008
Same author

[High time for wide application of an opting-out strategy for HIV testing].

Nederlands tijdschrift voor geneeskunde·2008
Same author

[Hepatitis C in the Netherlands: sparse data on the current prevalence and the necessity for epidemiological studies and innovative methods for detecting infected individuals].

Nederlands tijdschrift voor geneeskunde·2007
Same author

[Adverse events following influenza vaccination: reaction to specific reports and the necessity of a central registration system].

Nederlands tijdschrift voor geneeskunde·2007
Same author

Population-based study on the seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004.

Journal of medical virology·2007
Same author

Molecular epidemiology of acute hepatitis B in the Netherlands in 2004: nationwide survey.

Journal of medical virology·2007
Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026
Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026
Same journal

Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults.

Vaccine·2026
Same journal

Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls.

Vaccine·2026
Same journal

Public health benefits of maternal influenza vaccination among pregnant women and infants <6 months in the United States, 2011-2020.

Vaccine·2026
Same journal

Effectiveness and acceptability of an opt-out nudge to promote influenza vaccination among medical residents: A randomized controlled trial.

Vaccine·2026
See all related articles

Simultaneous administration of immune globulin (Ig) and hepatitis A vaccine provides immediate and long-term protection. However, Ig may reduce vaccine effectiveness, potentially necessitating an earlier booster dose.

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Hepatitis A virus (HAV) infection poses a public health risk.
  • Immune globulin (Ig) offers passive immunity, while vaccines induce active immunity.
  • Investigating combined passive and active immunization strategies is crucial for timely protection.

Purpose of the Study:

  • To evaluate the serum antibody response to simultaneous administration of immune globulin (Ig) and an inactivated hepatitis A vaccine.
  • To compare the immunogenicity and seropositivity rates between combined and individual administration of Ig and hepatitis A vaccine.
  • To assess the potential interference of Ig with the vaccine-induced immune response.

Main Methods:

  • A randomized controlled trial involving 149 healthy volunteers.

Related Experiment Videos

  • Three groups received: hepatitis A vaccine alone, Ig alone, or a combination of Ig and vaccine.
  • Serum antibody levels were measured using enzyme-linked immunosorbent assay (ELISA) at various time points.

    • Main Results:

    • The combination group achieved 100% seropositivity by day 5, month 1, and month 2, with sustained high rates.
    • Hepatitis A vaccine alone also demonstrated high seroconversion rates.
    • Geometric mean titres were approximately twofold lower in the combined group, suggesting Ig interference.

    Conclusions:

    • Simultaneous administration of hepatitis A vaccine and Ig provides both immediate passive protection and long-term active immunity.
    • The observed reduction in antibody titres indicates potential interference, possibly requiring an earlier booster dose.
    • This combined approach offers a viable strategy for rapid and sustained protection against Hepatitis A.